DRUG DELIVERY FABRIC HAVING DRUG-CONTAINING LAYER

Abstract

The present invention relates to a drug delivery fabric having a drug-containing layer, wherein the drug delivery fabric comprises a surface layer, a middle layer, and a drug-containing layer, the middle layer is formed of a yarn having hydrophilicity relatively equal to or higher than that of the surface layer, the drug-containing layer is formed of a cellulose derivative film containing a drug.

Claims

1. A drug delivery fabric having a drug-containing layer, wherein the drug delivery fabric includes a surface layer, a middle layer, and a drug-containing layer, the middle layer is formed of a yarn having hydrophilicity relatively equal to or higher than that of the surface layer, and the drug-containing layer is formed of a cellulose derivative film containing a drug.

2. The drug delivery fabric having a drug-containing layer of claim 1, wherein the middle layer has tissue density relatively higher than that of the surface layer.

3. The drug delivery fabric having a drug-containing layer of claim 1, wherein the surface layer is formed of any one of polypropylene-based fibers, polyester-based fibers, polyamide-based fibers, and cellulose-based fibers or by blending two or more fibers thereof.

4. The drug delivery fabric having a drug-containing layer of claim 1, wherein the middle layer is formed of any one of polyamide-based fibers, polyacryl-based fibers, polyester-based fibers, cellulose-based fibers, and protein-based fibers or by blending two or more fibers thereof.

5. The drug delivery fabric having a drug-containing layer of claim 1, wherein the drug contained in the drug-containing layer is included by encapsulation.

6. The drug delivery fabric having a drug-containing layer of claim 1, wherein the drug contained in the drug-containing layer is caffeine.

7. Clothes having a drug delivery function comprising the drug delivery fabric of any one of claims 1.

8. Clothes having a drug delivery function comprising the drug delivery fabric of claim 2.

9. Clothes having a drug delivery function comprising the drug delivery fabric of claim 3.

10. Clothes having a drug delivery function comprising the drug delivery fabric of claim 4.

11. Clothes having a drug delivery function comprising the drug delivery fabric of claim 5.

12. Clothes having a drug delivery function comprising the drug delivery fabric of claim 6.

Description

DESCRIPTION OF DRAWINGS

[0022] FIG. 1 is a cross-sectional view illustrating a drug delivery fabric having a drug-containing layer of the present invention.

[0023] FIG. 2 is a diagram of an exemplary embodiment of clothes manufactured by a fabric having a drug delivery function of the present invention.

[0024] FIG. 3 is a diagram illustrating a Franz diffusion cell capable of testing percutaneous absorption.

DESCRIPTION OF MAIN REFERENCE NUMERALS OF DRAWINGS

Best Mode

[0025] Hereinafter, preferred exemplary embodiments of the present invention will be described in detail with reference to the accompanying drawings. First, it should be noted that like reference numerals designate like constituent elements or components in the drawings. In describing the present invention, a detailed description of publicly known functions or configurations incorporated herein will be omitted so as not to make the subject matter of the present invention unclear.

[0026] The terms representing the degree used in this specification of ‘approximately’, ‘substantially’, and the like are used as the value or a meaning close to the value when unique manufacturing and material tolerances are proposed in the aforementioned meaning, and used for preventing the disclosed content in which accurate or absolute figures are mentioned in order to help in the understanding of the present invention from being wrongly used by unscrupulous infringers.

[0027] FIG. 1 is a cross-sectional view illustrating a drug delivery fabric having a drug-containing layer of the present invention and FIG. 2 is a diagram of an exemplary embodiment of clothes manufactured by a fabric having a drug delivery function of the present invention.

[0028] The present invention relates to a drug delivery fabric having a drug-containing layer, and as illustrated in FIG. 1, the fabric is a drug delivery fabric which is formed by a surface layer 100 that prevents the drug from being transferred to the outside of the skin, a middle layer 200 that transfers the drug toward the skin, and a drug-containing layer 300 that is formed of a cellulose derivative film containing the drug.

[0029] The middle layer 200 is formed of a yarn having hydrophilicity relatively equal to or higher than that of the surface layer 100 to prevent moisture from being transferred to the surface layer 100 from the middle layer 200 and needs to be formed to transfer the moisture to the middle layer 200 from the surface layer 100.

[0030] The surface layer 100 may be formed of any one of polypropylene-based fibers, polyester-based fibers, polyamide-based fibers, and cellulose-based fibers or by blending two or more fibers thereof. The middle layer 200 may be formed of any one of polyamide-based fibers, polyacryl-based fibers, polyester-based fibers, cellulose-based fibers, and protein-based fibers or by blending two or more fibers thereof. The surface layer 100 needs to be constituted to prevent hydrophilicity from being higher than that of the middle layer 200.

[0031] For moisture transfer in one direction between the surface layer 100 and the middle layer 200, the middle layer 200 may be formed to have tissue density relatively higher than that of the surface layer 100.

[0032] The surface layer 100 and the middle layer 200 are formed of respective fabrics and then may be formed by a laminating method and the like and may be formed of a double-woven fabric through weaving or knitting.

[0033] As such, when the drug delivery fabric is constituted by the middle layer 200 having the relatively high hydrophilicity and the high tissue density and the surface layer, by a capillary phenomenon due to a difference in tissue density between the surface layer 100 and the middle layer 200, the moisture or the drug absorbed in the surface layer 100 is transferred to the middle layer 200 having the high density and the high hydrophilicity.

[0034] The surface layer 100 and the middle layer 200 may be formed by further containing an elastic yarn in order to enhance skin adhesion. The elastic yarn may use polyurethane-based or copolymer polyester-based fibers.

[0035] The drug-containing layer 300 is formed of a cellulose derivative film containing the drug.

[0036] The cellulose derivative film is a film made of a water-soluble polymer called cellulose ether.

[0037] The cellulose may be made of an insoluble natural polymer having crystallinity of 30 to 65% due to intermolecular hydrogen bonding or a water-soluble polymer called cellulose ether through etherification.

[0038] The cellulose ether may include methylcellulose (MC), ethylcellulose (EC), hydroxyethylcellulose (HEC), hydroxyethylmethylcellulose (HEMC), hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), microcrystallin cellulose (MCC), carboxymethylcellulose (CMC), and the like, and the cellulose derivative film of the present invention may be manufactured by using the cellulose ether.

[0039] The cellulose derivative film containing the drug of the present invention may be manufactured by containing the drug when forming the film using the cellulose ether.

[0040] As one example, the film may be manufactured by a solvent casting method in which the drug is directly dissolved in a solution of 3 to 10% of cellulose ether such as methylcellulose, carboxymethylcellulose, and hydroxypropylmethylcellulose and then glycerol as a plasticizer is added. Alternatively, the film may be manufactured by a phase-inversion method in which the drug is dissolved in a solution of 5 to 15% of cellulose ether.

[0041] As another example, the film may be manufactured by a film type nanoweb by containing the drug in cellulose ether and nano-fiberizing through electro-spinning.

[0042] The content of the drug contained in the cellulose derivative film needs to be adjusted according to a used drug and may be contained with 0.1 to 10 wt % of the weight of the cellulose derivative film for strength or ductility of the cellulose derivative film.

[0043] Further, the drug contained in the cellulose derivative film may be decomposed at the time of manufacturing the film and thus the drug may be encapsulated to prevent the drug from being decomposed and then included in the film.

[0044] The encapsulation of the drug may be performed by general micro-encapsulation of the drug using a capsule wall material such as calcium carbonate, silk, collagen, cellulose, chitosan, gelatin, and casein phthalic anhydride or encapsulation of injecting the drug into porous particles such as silica, titanium oxide, and zeolite.

[0045] The drug may use any drug suitable for percutaneous absorption and may use caffeine having functions of decomposing cellulite composed of fat and fiber and decomposing body fat (visceral fat and subcutaneous fat).

[0046] By the drug delivery fabric having the drug-containing layer according to the present invention which is formed above, most of drugs through the percutaneous are absorbed through a space between the cells of the stratum corneum as illustrated in FIG. 2 and absorbed to the dermis through a living epidermis and from the dermis to the carpillary by a principle of being diffused and distributed through the stratum corneum.

[0047] After the drugs pass through the stratum corneum, the drugs are easily diffused and distributed because there is no material that inhibits the diffusion of the drugs, and thus in the drug delivery through the percutaneous, it is most important that the drugs rapidly pass through the stratum corneum.

[0048] As such, a speed at which the drug is percutaneously delivered is as illustrated in Equation 1 below as a percutaneous absorption kinetics.

[00001]$\begin{array}{cc}J=\mathrm{DK}.Math.\frac{C}{h}=\mathrm{PC}& \left[\mathrm{Equation}.Math..Math.1\right]\end{array}$

[0049] (K: Fat-soluble degree of drug, D: Diffusion coefficient, C: Drug concentration, h: Skin thickness)

[0050] The fat-soluble degree K of drug in the percutaneous absorption kinetics is a unique characteristic of the used drug and the skin thickness h is a unique characteristic of each person, and thus it is not easy to adjust the characteristics with the fabric.

[0051] The diffusion coefficient D is changed depending on hydration of the skin and a temperature, and as the skin is hydrated, the diffusion coefficient D increases as the temperature increases.

[0052] In the present invention, the drug-containing layer 300 made of the water-soluble polymer is in contact with the skin as illustrated in FIG. 2 and serves to hydrate the skin, promote the hydration of the skin by configuring the surface layer 100 and the middle layer 200 which transfer the moisture to the skin, and increase the diffusion coefficient D by adjusting the concentration.

[0053] Further, the drug-containing layer 300 prevents the drug from being transferred to the surface layer of the fabric to increase the concentration C of the drug which is in contact with the skin.

[0054] As such, the fabric having the drug delivery function of the present invention allows the drug to be delivered into the inside of the percutaneous by improving the percutaneous speed due to the increase in the diffusion coefficient D and the increase in concentration C of the drug in contact with the skin through the skin hydration.

[0055] Hereinafter, Examples of a method for manufacturing a drug delivery fabric having a drug-containing layer according to the present invention will be described, but the present invention is not limited to the Examples.

EXAMPLES 1 TO 4

[0056] A double-woven knitted fabric was manufactured by a fabric composition illustrated in Table 1 below to manufacture the surface layer 100 and the middle layer 200, a hydroxypropyl methylcellulose (HPMC) film was used as the drug-containing layer 300, and caffeine was used as the drug. The caffeine was contained in the film by adding 5% of a polymer weight when the film was manufactured.

[0057] The knitted fabric of the surface layer and the middle layer and the drug-containing layer are bonded to each other through a laminating method to manufacture the drug delivery fabric having the drug-containing layer of the present invention.

TABLE-US-00001 TABLE 1 Weight Classification Fiber type ratio Example 1 Surface layer Polypropylene fiber   37% Middle layer Modal fiber   63% Example 2 Surface layer Polyester fiber/cotton blended yarn   50% Middle layer Polyester fiber/cotton blended yarn   50% Example 3 Surface layer Polypropylene fiber 41.30% Middle layer Modal fiber 58.70% Example 4 Surface layer Polyester fiber 41.50% Middle layer Modal fiber 58.50%

[0058] Percutaneous Absorption Test

[0059] A percutaneous absorption test of the drug delivery fabric of Examples 1 to 4 manufactured above was performed. As Comparative Example, a caffeine-containing hydroxypropylmethylcellulose film manufactured in the Examples was used.

[0060] The percutaneous absorption test was performed by using a Franz diffusion Cell which may test percutaneous absorption of FIG. 3 and PBS saline was used as a receptor chamber.

[0061] Results of the percutaneous absorption test in Examples 1 to 4 and Comparative Example were in Table 2.

TABLE-US-00002 TABLE 2 Classification 0H 2H 4H 6H 8H 10H 12H Example 1 0 58.2 104.0 156.6 172.3 186.0 228.1 Example 2 0 21.6 34.0 54.6 62.6 64.0 64.6 Example 3 0 35.1 60.6 97.1 112.1 125.1 144.5 Example 4 0 21 29.8 48.8 63.5 67.1 69.2 Comparative Example 0 9.9 18.1 29.7 39.6 42.9 47.8

[0062] As illustrated in Table 2, as compared with the case of using only the HPMC film in Comparative Example, in Example which was the drug delivery fabric having the drug-containing layer of the present invention, it can be seen that a percutaneous absorption rate is excellent as at least 50% or more, and in the case of Example 1, it can be seen that the percutaneous absorption rate is 5 times larger than that of Comparative Example.

[0063] Therefore, in the drug delivery fabric having the drug-containing layer of the present invention, it can be seen that the drug delivery function through the percutaneous is very excellent.